Incidence and Clinical Features of PHACE Syndrome
Incidence, Risk Factor and Clinical Features of PHACE Syndrome
This study will include infants seen at three hospitals who have a segmental infantile hemangioma, a blood vessel growth affecting a broad area of skin. Eligible areas include the scalp, face, neck, upper chest or back, and shoulder or upper arm. The study will measure how often PHACE syndrome is found in infants with enough clinical information to determine the diagnosis. PHACE syndrome can involve differences in the development of the brain, arteries, heart, eyes, or the midline of the chest and abdomen. The study team will describe these findings and the hemangiomas. The treating clinicians will manage evaluation and care.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Gedetailleerde beschrijving
This prospective observational cohort will consecutively invite infants with a clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity at their first qualifying presentation to a participating center. Infants can enroll regardless of whether a PHACE evaluation or diagnosis is already documented. Prior evaluation and referral source will be recorded. Each infant will be enrolled once. A parent or legal guardian will provide written informed consent.
At enrollment, study clinicians will record age, sex, the anatomic distribution and laterality of the segmental lesions, the longest diameter of the largest qualifying lesion, and lesion depth. Photographs will be recorded when permitted by the protocol and consent. Each infant will be assigned to one anatomic stratum. The strata are head involvement with or without other sites, isolated neck, isolated upper trunk, isolated proximal upper extremity, and multiple sites without head involvement. All involved regions will also be recorded.
The study will collect clinical findings and results of clinically indicated assessments, including examination for ocular and ventral midline abnormalities, echocardiography, and magnetic resonance imaging and angiography of the head and neck, with aortic arch assessment. The treating team will determine which examinations and treatments are clinically appropriate. Prior assessments can contribute to classification when they meet the same protocol criteria for adequacy.
A central panel will apply the revised 2016 PHACE consensus diagnostic criteria. A hemangioma of the head, including the scalp, that exceeds 5 cm in diameter supports a diagnosis of definite PHACE when accompanied by at least one major or two minor criteria. For large segmental hemangiomas of the neck, upper trunk, or trunk with proximal upper-extremity involvement, definite PHACE requires at least two major criteria. Isolated proximal upper-extremity lesions will be described separately. Classification as definite PHACE will require documented fulfillment of the consensus criteria.
The primary analysis will include infants with a protocol-defined evaluable assessment by six months after enrollment. An evaluable assessment requires interpretable documentation of the prespecified core clinical, cardiac, and neurovascular evaluations, irrespective of the diagnostic classification. Definite PHACE, possible PHACE, and neither category will be reported separately. Inadequate evaluations will be recorded with the reason and retained in the enrollment count. The study will report the assessment completion proportion and the definite PHACE proportion with 95% confidence intervals overall and by anatomic stratum where estimable.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Yi Ji Ji, PhD
- Telefoonnummer: 02885423453
- E-mail: jijiyuanyuan@163.com
Studie Locaties
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 610041
- Werving
- Children's Hospital of Fudan University
-
Contact:
- Zuopeng Wang Wang, PhD
- Telefoonnummer: 028854223
- E-mail: 1192207223@qq.com
-
-
Sichuan
-
Chengdu, Sichuan, China
- Werving
- West China Hospital of Sichuan University
-
Contact:
- Yi Ji Ji, PhD
- Telefoonnummer: 02885423453
- E-mail: jijiyuanyuan@163.com
-
Chengdu, Sichuan, China
- Werving
- West China Second Hospital of Sichuan University
-
Contact:
- Hu Fan Hu, PhD
- Telefoonnummer: 02885423452
- E-mail: 1901613702@qq.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Infants from birth through 12 months of age at their first qualifying presentation during the recruitment period at one of the three participating centers, with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
Beschrijving
Inclusion Criteria
- From birth through 12 months of chronological age at enrollment.
- Clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
- First qualifying presentation at a participating center during the recruitment period.
- Written informed consent from a parent or legal guardian.
Exclusion Criteria
- The lesion responsible for eligibility is subsequently adjudicated to be a different vascular anomaly, such as a congenital hemangioma or vascular malformation.
- Prior enrollment in this study at any participating center.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Aantal groepen / cohorten
Cohorten en interventies
Groep / CohortGroep / Cohort |
|---|
|
Infants With Segmental Infantile Hemangiomas
Infants with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity who are enrolled at one of the three participating centers. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of Evaluable Infants With PHACE Syndrome
Tijdsspanne: At enrollment through 6 months after enrollment.
|
Percentage of infants with an evaluable PHACE assessment who fulfill the revised 2016 consensus criteria for PHACE. Evaluable assessments have the prespecified core clinical, cardiac, and neurovascular evaluations documented and interpretable. Each infant is counted once. |
At enrollment through 6 months after enrollment.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Anatomic Distribution and Laterality of Segmental Hemangiomas
Tijdsspanne: At enrollment.
|
Number and percentage of infants by involved anatomic region and lesion laterality (left, right, bilateral, or midline) among infants with evaluable lesion documentation. |
At enrollment.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Haggstrom AN, Garzon MC, Baselga E, Chamlin SL, Frieden IJ, Holland K, Maguiness S, Mancini AJ, McCuaig C, Metry DW, Morel K, Powell J, Perkins SM, Siegel D, Drolet BA. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010 Aug;126(2):e418-26. doi: 10.1542/peds.2009-3166. Epub 2010 Jul 19.
- Garzon MC, Epstein LG, Heyer GL, Frommelt PC, Orbach DB, Baylis AL, Blei F, Burrows PE, Chamlin SL, Chun RH, Hess CP, Joachim S, Johnson K, Kim W, Liang MG, Maheshwari M, McCoy GN, Metry DW, Monrad PA, Pope E, Powell J, Shwayder TA, Siegel DH, Tollefson MM, Vadivelu S, Lew SM, Frieden IJ, Drolet BA. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr. 2016 Nov;178:24-33.e2. doi: 10.1016/j.jpeds.2016.07.054. Epub 2016 Sep 19. No abstract available.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 20220212
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .